Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Stock

Posted by Mitch Edgeman on Nov 7th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $26.53, for a total transaction of $315,202.93. Following the sale, the chief operating officer owned 377,802 shares of the company’s stock, valued at approximately $10,023,087.06. This represents a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.73, for a total value of $317,579.13.
On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.47, for a total value of $302,609.07.
On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total value of $338,014.45.
On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total transaction of $296,787.38.
On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total transaction of $285,738.05.
On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total transaction of $301,896.21.
On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.61, for a total transaction of $304,272.41.
On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.50, for a total transaction of $302,965.50.
On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.66, for a total transaction of $304,866.46.

Adaptive Biotechnologies Trading Up 4.3%

Shares of ADPT stock opened at $27.98 on Friday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The company has a market cap of $4.47 billion, a price-to-earnings ratio of -62.18 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $30.74. The firm has a fifty day moving average price of $26.42 and a 200-day moving average price of $19.86.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.12. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $71.57 million. During the same period in the previous year, the business earned $0.06 earnings per share. Adaptive Biotechnologies’s quarterly revenue was down 10.7% compared to the same quarter last year. As a group, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.40 earnings per share for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. raised its holdings in Adaptive Biotechnologies by 14.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 89,721 shares of the company’s stock valued at $2,593,000 after buying an additional 10,999 shares during the period. Mesirow Financial Investment Management Inc. bought a new position in Adaptive Biotechnologies during the third quarter valued at $252,000. University of Texas Texas AM Investment Management Co. bought a new position in Adaptive Biotechnologies during the third quarter valued at $277,000. Ethic Inc. purchased a new stake in shares of Adaptive Biotechnologies in the third quarter valued at $244,000. Finally, Pictet Asset Management Holding SA raised its stake in shares of Adaptive Biotechnologies by 12.5% in the third quarter. Pictet Asset Management Holding SA now owns 17,924 shares of the company’s stock valued at $518,000 after acquiring an additional 1,985 shares during the period. 99.17% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on ADPT. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Thursday, October 15th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. BTIG Research increased their price objective on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. The Goldman Sachs Group initiated coverage on Adaptive Biotechnologies in a research report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price objective for the company. Finally, National Bank Financial set a $34.00 target price on Adaptive Biotechnologies in a research report on Tuesday, September 22nd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $30.06.

View Our Latest Stock Report on ADPT

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.